In the EU joint clinical assessment, the questions your dossier must answer are set through a scoping exercise in which the developer has very limited influence. Understanding how the PICO scope is built is the first step to preparing evidence for it.
What the scope is
Under Implementing Regulation (EU) 2024/1381, the assessment scope is defined by PICOs: Patient, Intervention, Comparator and Outcomes. It must be inclusive of all Member States needs, so Member States may propose PICOs, and patient and clinical experts are consulted. The aim is a set of questions that national HTA bodies can all use, which can mean several comparators and outcomes for one product.
What the developer does and does not do
- At the start of the process the developer submits the summary of product characteristics and the clinical overview from the marketing authorisation application.
- The developer is not expected to provide other information unless the Coordination Group asks for it, and has no right to comment on the scope, unlike clinical experts and patients.
- If requested, an explanation meeting is held after the scope is adopted.
- The developer learns the final scope when the Commission requests the dossier, and the dossier is due within 100 days.
Why this matters for evidence planning
Because scoping largely precedes dossier work, preparation has to happen earlier, using the likely PICOs rather than the final ones. Published commentary on the process describes a typical scoping phase of a few months, but the exact steps and timings should be checked against the regulation and current HTA Coordination Group guidance.
- Map the likely comparators across Member States, including Greece, well before filing.
- Identify where the pivotal trial design will and will not support those comparisons.
- Plan indirect comparisons and sensitivity analyses early, and document the rationale.
- Use joint scientific consultation where eligible to test the evidence plan.
Where we see risk
The main risks are late discovery that a comparator in the final scope is not covered by the trial, and treating the JCA as a copy of the national dossier. The JCA is a clinical assessment and reports on relative effectiveness and certainty of evidence, while pricing and reimbursement remain national.
How PQRA helps
PQRA helps companies anticipate the PICO landscape, identify evidence gaps against likely comparators, and prepare JCA-ready evidence plans that also feed the Greek HTA and reimbursement submission.
Planning evidence for a JCA-scope product? Contact PQRA for a practical discussion.


No responses yet